Your Health, We Care
Afatinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
The safety and efficacy of Afatinib have not been established in patients whose tumors have resistant EGFR mutations.
Afatinib is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.
from FDA，2022.04
LuciusVersionofAfatinib:DosageandAdministration,Indications,PrecautionsIndicationsAfatinib is a kina···【more】
Recommended：1142025-11-12
As a targeted therapeutic agent, the dosage and administration of afatinib should be individually adjusted based on the patient’s specific condition, body surface area and tolerabi···【more】
Article source：Lucius LaosRelease date：2026-03-31Recommended：30
Afatinib can be used to treat Non Small Cell Lung Cancer.【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：35
LuciusVersionofAfatinib:DosageandAdministration,Indications,PrecautionsIndicationsAfatinib is a kinase inhibitor indicated for:First-line treatment of patients with metastatic non-···【more】
Article source：Lucius LaosRelease date：2025-12-11Recommended：114
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
